Dr Elena Castro

Consultant Medical Oncologist

Hospital Universitario Virgen de la Victoria
Málaga, Spain
DISCLOSURES

Participation in advisory boards: Astra-Zeneca, Astellas, Bayer, Janssen, MSD

Research funding: Astra Zeneca, Bayer, Janssen, Synlab

Speaker fees: Astra Zeneca, Astellas, Bayer, Clovis, Janssen, MSD, Pfizer, Roche

Travel, accommodation, expenses: Astellas, Astra-Zeneca, Bayer, Janssen

 Prostate cancer is the second most common cancer in men worldwide

https://gco.iarc.fr/ accessed March, 2021. https://gco.iarc.fr/ accessed March, 2021.

 Incidence and mortality vary widely across the world

https://gco.iarc.fr/ accessed March, 2021. https://gco.iarc.fr/ accessed March, 2021.

RISK FACTORS FOR PROSTATE CANCER

de Bono J, Gillessen S, Methra N and Loriot Y, eds. Genitourinary Tract Tumours -

Eeles R, et al. Nat Rev Urol 2014;11(1):18-31.
Essentials for Clinicians, 2nd Edition. ESMO Press, Lugano, 2020.
 NATURAL HISTORY OF PROSTATE CANCER

<10%
de novo
METASTATIC
CPRC_M1
DISEASE
M1

METASTATIC
RECURRENCE
>90% M1

LOCALIZED DISEASE Biochemical

M0 Relapse CPRC_M1
M0
NON METASTATIC
CASTRATION
RESISTANCE
nmCRPC
GENOMIC LANDSCAPE OF PROSTATE CANCER
Localized PC mCRPC

Actionable alterations in most mCRPC patients

AR pathway: 70%
PI3K-AKT-mTOR: 40-60%
DDR: 25%
Cell cycle regulators RB1/CDK: 25%
Others
The Cancer Genome Atlas Research Network. Cell 2015; 163(4):1011-1025. Robinson D, et al, Cell 2015; 161(5):1215-1228.
 HIGHER PREVALENCE OR GENOMIC ALTERATIONS IN ADVANCED
PROSTATE CANCER
Localized PC

Metastatic PC

Mateo J, et al. Nat Cancer 2020; 1:1041-1053. Mateo J, et al. Nat Cancer 2020; 1:1041-1053.
PRECISION MEDICINE FOR ADVANCED PROSTATE CANCER

Elena Castro MD PhD

Ku S-Y, et al. Nat Rev Urol 2019; 16(11):645-654.

ALTERATIONS IN AR PATHWAY ARE THE MOST PREVALENT
BIOLOGICAL EVENTS IN MCRPC

Ku S-Y, et al. Nat Rev Urol 2019; 16(11):645-654. Ku S-Y, et al. Nat Rev Urol 2019; 16(11):645-654.
PRECISION MEDICINE FOR ADVANCED PROSTATE CANCER

Elena Castro MD PhD

Ku S-Y, et al. Nat Rev Urol 2019; 16(11):645-654.

PREVALENCE OF SOME TARGETABLE GENES FREQUENT ALTERED
IN ADVANCED PROSTATE CANCER
BRCA2
BRCA1
ATM

CDK12

Other HRR

AKT/PIK3CA/PIK3CB MMR

PTEN